Trending

HER2-positive breast cancer

ESMO21: Enhertu brings it’s A game to second-line breast cancer

ESMO21: Enhertu brings it’s A game to second-line breast cancer

AstraZeneca and Daiichi Sankyo were clearly excited by data from a trial pitting their HER2 antibody-drug conjugate (ADC)

X

ESMO21: Enhertu brings it’s A game to second-line breast cancer

https://pharmaphorum.com/news/esmo21-enhertu-brings-its-a-game-to-second-line-breast-cancer/

MHRA approves Seagen’s oral HER2 drug Tukysa

MHRA approves Seagen’s oral HER2 drug Tukysa

The UK drugs regulator has approved Seagen’s Tukysa as a third-line treatment for HER2-positive breast cancer, shortly after

X

MHRA approves Seagen’s oral HER2 drug Tukysa

https://pharmaphorum.com/news/mhra-approves-seagens-oral-her2-drug-tukysa/

Roche claims EU okay for Herceptin/Perjeta combination Phesgo

Roche claims EU okay for Herceptin/Perjeta combination Phesgo

Roche has secured EU approval for Phesgo, a fixed-dose combination of its breast cancer drugs Herceptin and Perjeta

X

Roche claims EU okay for Herceptin/Perjeta combination Phesgo

https://pharmaphorum.com/news/roches-claims-eu-okay-for-herceptin-perjeta-combination-phesgo/

Puma Biotechnology’s breast cancer drug approved in Europe

Puma Biotechnology received European Commission (EC) marketing authorisation for Nerlynx (neratinib) in breast cancer, despite earlier European Medicines

X

Puma Biotechnology’s breast cancer drug approved in Europe

https://pharmaphorum.com/news/ec-approves-puma-breast-cancer-drug/

Pfizer wins Herceptin biosimilar approval in Europe

European Commission (EC) has approved Pfizer’s Trazimera, for breast and gastric cancer treatment, marking it as pharma’s first

X

Pfizer wins Herceptin biosimilar approval in Europe

https://pharmaphorum.com/news/herceptin-biosimilar-european-approval/

Roche’s Perjeta combo approved in Europe for early breast cancer

Roche’s Perjeta combo approved in Europe for early breast cancer

The European Commission (EC) has approved Roche’s Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy for post-surgery (adjuvant) treatment of adult patients with HER2-positive early breast cancer (eBC) at high risk of recurrence.

X

Roche’s Perjeta combo approved in Europe for early breast cancer

https://pharmaphorum.com/news/roches-perjeta-approved-early-breast-cancer/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com